Last update 21 Jun 2024
EGb-761
Last update 21 Jun 2024
Overview
Basic Info
Drug Type Small molecule drug |
Synonyms Gingogink, Ginkgo biloba special extract, Levamisole hydrochloride + [4] |
Target |
Mechanism NOS2 inhibitors(Nitric oxide synthase, inducible inhibitors), Platelet aggregation inhibitors |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date FR (28 Feb 2002), |
Regulation- |
Login to view First Approval Timeline
Structure
Molecular FormulaC11H13ClN2S |
InChIKeyLAZPBGZRMVRFKY-HNCPQSOCSA-N |
CAS Registry16595-80-5 |
Related
16
Clinical Trials associated with EGb-761An Observational, Open Label, Post Marketing Study to Evaluate the Safety and Effectiveness of Hoat Huyet Nhat Nhat Compared With Gingko Biloba EGb761 (Tanakan 40mg) in Patients With Symptoms Related to the Insufficient Blood Supply to the Brain
Non-interventional Prospective Observational Study to Describe EGB 761® (Tanakan®) Effectiveness in the Treatment of Patients of Middle Age and Younger With Psycho-emotional Symptoms, Added to Cognitive Disorders.
Randomized, open-label, parallel-group study to assess the feasibility of patient selection, treatment regimen and outcome measures and to obtain preliminary data for sample size estimation for a trial to evaluate treatment effects on cognitive and emotional functioning of Ginkgo biloba extract EGb 761® in patients who had suffered an acute ischemic stroke
100 Clinical Results associated with EGb-761
Login to view more data
100 Translational Medicine associated with EGb-761
Login to view more data
100 Patents (Medical) associated with EGb-761
Login to view more data
933
Literatures (Medical) associated with EGb-76101 Dec 2023Journal of trace elements in medicine and biology : organ of the Society for Minerals and Trace Elements (GMS)
Enhanced expression of RAGE/NADPH oxidase signaling pathway and increased level of oxidative stress in brains of rats with chronic fluorosis and the protective effects of blockers
Article
Author: Ma, Yan-Lin ; Zhang, Kai-Lin ; Deng, Jie ; Zhang, Ting ; Liang, Qiu-Zhe ; Li, Hong-Mei
This investigation was designed to examine the potential involvement of RAGE/NADPH oxidase signaling in the damage to the brain caused by chronic fluorosis. Sprague-Dawley rats were divided randomly into 9 groups each containing 20 animals, Controls (C); rats receiving low (i.e., 10 ppm) (LF) or high does ( i.e., 50 ppm) (HF) of fluoride in their drinking water; and these same groups injected with FPS-ZM1, an inhibitor of RAGE, (CF, LFF and HFF, respectively) or administered EGb761, an active ingredient of Ginkgo biloba extract, intragastrically (CE, LFE, and HFE). Following 3 and 6 months of such treatment, the spatial learning and memory of the animals were assessed with the Morris water maze test; the levels of malondialdehyde (MDA), hydrogen peroxide (H2O2) and superoxide dismutase (SOD) assayed by biochemical methods; and the levels of proteins related to the RAGE/NADPH pathway determined by Western blot and of the corresponding mRNAs by qPCR. After 6 months, the spatial learning and memory of the LF and HF groups had declined; their brain contents of MDA and H2O2 increased and SOD activity decreased; and the levels of the RAGE, gp91, P47, phospho-P47phox and P22 proteins and corresponding mRNAs in their brains were all elevated. Interestingly, all of these pathological changes caused by fluorosis could be attenuated by both FPS-ZM1 and EGb761. These findings indicate that the brain damage induced by fluorosis may be caused, at least in part, by enhanced RAGE/NADPH oxidase signaling and that FPS-ZM1 or EGb761 might be of clinical value in connection with the treatment of this condition.
The International journal of neuroscience
Evaluating the role of Ginkgo biloba extract in the secondary prevention of acute ischemic stroke with cerebral microbleeds by quantitative susceptibility mapping (QSM)
Article
Author: Zhang, Hui ; Wu, Yuefei ; Wu, Xin ; Lan, Wenting
BACKGROUND:
EGb 761, a standardized dry extract of Ginkgo biloba leaves, has certain anti-inflammatory and thrombotic effects and can be used to treat cerebrovascular diseases.
METHODS:
A total of 49 patients were randomly assigned to the Aspirin group (24 cases in Controlled group) and the Aspirin + Ginkgo biloba group (25 cases in Treatment group). The quantitative magnetic sensitivity and venous oxygen saturation of cerebral microbleeds were analyzed at admission, discharge, and after follow-up for 3 and 6 months.
RESULTS:
The demographic details age, gender, and admission to NIHSS were not significantly different between the two groups (p < 0.05). Quantitative susceptibility mapping (QSM) showed that the magnetic sensitivity of patients in both groups remained stable after 3 and 6 months of follow-up, while the venous oxygen saturation of the Treatment group increased. The venous oxygen saturation at 3 and 6 months of follow-up was negatively correlated with the modified mRS grade score.
CONCLUSIONS:
QSM can be used as a quantitative follow-up tool in monitoring both oxygen saturation and Magnetic susceptibility of microbleeds noninvasively in ischemic stroke patients with cerebral microbleeds. EGB combined with Aspirin can improve blood oxygen saturation in those patients and this effect is particularly significant in the long-term efficacy of secondary prevention.
15 Sep 2023Journal of neuroimmunology
Ginkgo biloba extract (EGb-761) confers neuroprotection against ischemic stroke by augmenting autophagic/lysosomal signaling pathway.
Article
Author: Lv, Zuyin ; Wu, Zhiyuan ; Ling, Fayang ; Sun, Jun ; Ji, Nengbo ; Yang, Licong ; Zang, Rui
Ginkgo biloba extract (EGb-761) is well-recognized to have neuroprotective properties. Meanwhile, autophagy machinery is extensively involved in the pathophysiological processes of ischemic stroke. The EGb-761 is widely used in the clinical treatment of stroke patients. However, its neuroprotective mechanisms against ischemic stroke are still not fully understood. The present study was conducted to uncover whether the pharmacological effects of EGb-761 can be executed by modulation of the autophagic/lysosomal signaling axis. A Sprague-Dawley rat model of ischemic stroke was established by middle cerebral artery occlusion (MCAO) for 90 min, followed by reperfusion. The EGb-761 was then administered to the MCAO rats once daily for a total of 7 days. Thereafter, the penumbral tissues were acquired to detect proteins involved in the autophagic/lysosomal pathway including Beclin1, LC-3, SQSTM1/p62, ubiquitin, cathepsin B, and cathepsin D by western blot and immunofluorescence, respectively. Subsequently, the therapeutic outcomes were evaluated by measuring the infarct volume, neurological deficits, and neuron survival. The results showed that the autophagic activities of Beclin1 and LC3-II in neurons were markedly promoted by 7 days of EGb-761 therapy. Meanwhile, the autophagic cargoes of insoluble p62 and ubiquitinated proteins were effectively degraded by EGb-761-augmented lysosomal activity of cathepsin B and cathepsin D. Moreover, the infarction size, neurological deficiencies, and neuron death were also substantially attenuated by EGb-761 therapy. Taken together, our study suggests that EGb-761 exerts a neuroprotective effect against ischemic stroke by promoting autophagic/lysosomal signaling in neurons at the penumbra. Thus, it might be a new therapeutic target for treating ischemic stroke.
1
News (Medical) associated with EGb-761100 Deals associated with EGb-761
Login to view more data
R&D Status
Approved
10 top approved records. to view more data
Login
Developing
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Tinnitus | Phase 3 | CZ | 01 Jun 2012 | |
| Cognition Disorders | Phase 3 | FR | - | 11 Aug 2010 |
| Cognitive Dysfunction | Phase 3 | FR | 26 Aug 2003 | |
| Multiple Sclerosis, Relapsing-Remitting | Phase 3 | FR | 26 Aug 2003 | |
| Ischemic stroke | Phase 3 | CZ | 01 Feb 2003 | |
| Ischemic stroke | Phase 3 | PL | 01 Feb 2003 | |
| Ischemic stroke | Phase 3 | RO | 01 Feb 2003 | |
| Ischemic stroke | Phase 3 | RU | 01 Feb 2003 | |
| Nerve injury | Phase 3 | CZ | 01 Feb 2003 | |
| Nerve injury | Phase 3 | PL | 01 Feb 2003 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Phase 3 | 204 | (EGb761®) | zdlxosstqd(qhtdmskpef) = urjinmhlol etrkuijezu (rqvwnaetyc, jlnybcedgk - jnyggkxieg) View more | - | 19 Feb 2018 | ||
placebo+Acetylsalicylic acid (Placebo) | zdlxosstqd(qhtdmskpef) = ctrlwqwdbh etrkuijezu (rqvwnaetyc, yclfadwqfr - sadbcjfpyb) View more | ||||||
Phase 2 | 49 | EGb (EGb 120 mg (Open Phase - CNE)) | mzkxxubjal(xwajkoxoap) = rxftayngqp lvvxzfxykc (mkuwmxplks, tbqlphglee - lqloihzcwr) View more | - | 28 Mar 2016 | ||
EGb (EGb 120 mg (Open Phase - MC)) | mzkxxubjal(xwajkoxoap) = qsjtlqreww lvvxzfxykc (mkuwmxplks, nwuafzucvt - dkdufdrwlb) View more | ||||||
Phase 2 | 22 | (EGb 761® 120 mg) | mkthcyngng(yzgvmdsnuw): P-Value = 0.9133 | - | 21 May 2013 | ||
placebo (Placebo) | |||||||
Phase 3 | 3,069 | (Ginkgo Biloba) | cgxpslzwqd(pesqdoudrv) = keexpbhzut pwclwuhxri (wgrasfkfgk, weoopbmtmo - jndyodjakt) View more | - | 16 Sep 2010 | ||
Placebo (Placebo) | cgxpslzwqd(pesqdoudrv) = puualzrlie pwclwuhxri (wgrasfkfgk, abcxielpnj - pvgfvbzlit) View more | ||||||
Not Applicable | 410 | dscvvnzlsd(tfgrzwqcab) = hequcrfkrw qtveewftrn (yjrlzbiutl ) View more | Positive | 01 Jul 2008 | |||
Placebo | dscvvnzlsd(tfgrzwqcab) = mblepzjwst qtveewftrn (yjrlzbiutl ) View more |
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free